Walsh & Associates’s AbbVie ABBV Stock Holding History

Walsh & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$203K	Buy	808 +165	+26%	+$35.5K	0.17%	55
2026 Q1	$140K	Buy	643 +2	+0.3%	+$444	0.14%	62
2025 Q4	$146K	Buy	+641	New	+$146K	0.14%	62

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Walsh & Associates's ABBV Position: Q2 2026 in Review

Walsh & Associates increased its AbbVie (ABBV) stake by 26% in Q2 2026, buying an estimated $35.5K and bringing the position to 808 shares worth $203K. The position accounts for 0.17% of the portfolio, ranked #55.

Walsh & Associates first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Walsh & Associates held 808 shares of AbbVie worth $203K as of Q2 2026.
Walsh & Associates bought 165 AbbVie shares in Q2 2026, an estimated $35.5K.
AbbVie made up 0.17% of Walsh & Associates's portfolio in Q2 2026, its #55 holding.
Walsh & Associates first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Walsh & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.